Skip to content
Longterm Wiki
Back

Nature analysis of publication patterns

paper

Author

Priyanga Amarasekare

Credibility Rating

5/5
Gold(5)

Gold standard. Rigorous peer review, high editorial standards, and strong institutional reputation.

Rating inherited from publication venue: Nature

While this Nature article covers a medical breakthrough in cystic fibrosis treatment, it is not directly relevant to AI safety research, policy, or governance.

Paper Details

Citations
0
Year
2010
Categories
Faculty Opinions – Post-Publication Peer Review of

Metadata

news articlenews

Summary

A Nature article reports that the developers of Trikafta, a triple-drug combination treatment for cystic fibrosis, have won a US$3-million Breakthrough Prize. Trikafta has proven transformative for approximately 90% of cystic fibrosis patients by targeting the malformed proteins at the root of the disease. The award recognizes this significant medical breakthrough that has substantially improved outcomes for people with this inherited disorder affecting the lungs and other organs.

Cited by 1 page

PageTypeQuality
International AI Coordination Game ModelAnalysis59.0

Cached Content Preview

HTTP 200Fetched Mar 15, 20269 KB
Life-changing cystic fibrosis treatment wins US$3-million Breakthrough Prize 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 

 
 
 

 
 

 
 
 
 
 
 
 
 
 
 
 
 

 
 
 

 
 
 
 

 
 
 
 

 
 

 

 

 

 

 
 
 
 

 
 
 
 
 
 
 Skip to main content 

 
 
 
 Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
 the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
 Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
 and JavaScript.

 
 

 

 

 
 
 

 
 
 Advertisement

 
 
 
 
 
 
 
 
 
 
 

 
 
 
 

 

 
 
 
 

 

 

 

 
 
 
 

 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Email 
 
 
 

 
 
 Bluesky 
 
 
 

 
 
 Facebook 
 
 
 

 
 
 LinkedIn 
 
 
 

 
 
 Reddit 
 
 
 

 
 
 Whatsapp 
 
 
 

 
 
 X 
 
 
 

 

 
 

 
 

 
 
 
 
 
 
 
 
 
 
 Access through your institution 
 
 
 
 
 
 
 
 Buy or subscribe 
 
 
 
 
 
 

 
 
 

 
 

 

 
 The triple-drug combination Trikafta has given a new lease of life to 90% of people with cystic fibrosis, an inherited disorder that affects the lungs and other organs. Now, the trio of researchers who spearheaded its development has won one of this year’s US$3-million Breakthrough prizes — the most lucrative awards in science.

 
 Access options

 

 
 
 
 
 
 
 
 
 Access through your institution 
 
 
 
 
 
 

 
 
 
 
 
 Access Nature and 54 other Nature Portfolio journals
 

 
 Get Nature+, our best-value online-access subscription
 

 
 
 $32.99 / 30 days 
 

 cancel any time

 
 
 Learn more 
 
 
 
 
 Subscribe to this journal

 
 Receive 51 print issues and online access
 

 
 
 $199.00 per year

 only $3.90 per issue

 
 
 
 
 Learn more 
 
 
 
 
 
 Rent or buy this article

 Prices vary by article type

 from $1.95

 to $39.95

 
 Learn more 
 
 
 Prices may be subject to local taxes which are calculated during checkout

 
 

 
 
 
 

 
 
 
 
 
 Nature 621 , 450-451 (2023)

 doi: https://doi.org/10.1038/d41586-023-02890-1 

 
 References

 Riordan, J. R. et al. Science 245 , 1066–1073 (1989).

 Article  
 PubMed  
 
 Google Scholar  
 

 Lopez, A., Daly, D., Vega-Hernandez, G., MacGregor, G. & Rubin, J. L. J. Cyst. Fibros. 22 , 607–614 (2023).

 Article  
 PubMed  
 
 Google Scholar  
 

 Keating, D. et al. N. Engl. J. Med. 379 , 1612–1620 (2018).

 Article  
 PubMed  
 
 Google Scholar  
 

 Sidransky, E. et al. N. Engl. J. Med. 361 , 1651–1661 (2009).

 Article  
 PubMed  
 
 Google Scholar  
 

 Gilks, W. P. et al. Lancet 365 , 415–416 (2005).

 Article  
 PubMed  
 
 Google Scholar  
 

 Zimprich, A. et al. Neuron 44 , 601–607 (2004).

 Article  
 PubMed  
 
 Google Scholar  
 

 Rizig, M. et al. Lancet Neurol . https://doi.org/10.1016/S1474-4422(23)00283-1 (2023).

 Article  
 PubMed  
 
 Google Scholar  
 

 Brentjens, R. J. et al. Nature Med. 9 , 279–286 (2003).

 Article  
 PubMed  
 
 Google Scholar

... (truncated, 9 KB total)
Resource ID: 51d88490769a4fc2 | Stable ID: ZGUxYjU2M2